Luigi Gravara-Della

Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

RAS Inhibitors: Changing the Paradigm from the Undruggable.

RAS Inhibitors: Changing the Paradigm from the Undruggable.

Journal: Pharmaceutics

Published: April 30, 2026

Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies.

Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies.

Journal: Expert opinion on biological therapy

Published: September 05, 2025

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Journal: Journal for immunotherapy of cancer

Published: July 31, 2025

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Journal: Journal for immunotherapy of cancer

Published: December 29, 2024

RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy.

RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy.

Journal: Pathologica

Published: April 19, 2024

Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

Journal: Cancers

Published: August 01, 2023

Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer.

Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer.

Journal: Expert opinion on biological therapy

Published: February 21, 2023

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.

Journal: International journal of molecular sciences

Published: December 22, 2022

The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them.

The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: June 21, 2022

Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406].

Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406].

Journal: ESMO open

Published: April 04, 2022

Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?

Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?

Journal: Expert review of anticancer therapy

Published: January 06, 2022

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.

Journal: Journal of hematology & oncology

Published: November 12, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026